NHS England announced on Friday that it plans to recruit hundreds of pharmacists...
- Pfizer’s rituximab biosimilar edges closer to approval
- Digital health: a new direction for neurology
- China FDA replaced by State Drug Administration in proposed reform
- Deals this Week: Supernus Pharmaceuticals, Vanda Pharmaceuticals, Intellipharmaceutics International
- M&As this week: Seattle Genetics, Gryphon Investors, ChrysCapital
Pfizer’s rituximab biosimilar edges closer to approval
Pfizer’s rituximab biosimilar candidate, PF-05280586, edged closer towards approval on January 24, 2018, when the company announced positive top-line results in a Phase III trial in follicular lymphoma (FL).
FDA expands lymphoma indications for Seattle Genetics’ Adcetris
The US Food and Drug Administration (FDA) has approved Seattle Genetics’ Adcetris (brentuximab vedotin) to be given in combination with chemotherapy to treat adults with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL).
NHS to recruit 240 pharmacists to combat care home overmedication
NHS England announced on Friday that it plans to recruit hundreds of pharmacists to work in care homes to help reduce overmedication.
Pistoia Alliance calls life sciences firms to support ‘lab of the future’
Global non-profit organisation The Pistoia Alliance is urging the life sciences industry to join its efforts in creating the ‘lab of the future’ (LoTF) through greater collaboration.
Pfizer’s sNDA for Xtandi gets priority review for prostate cancer
Pfizer and Astellas Pharma have obtained priority review status from the US Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) of Xtandi (enzalutamide) to treat patients with non-metastatic castration-resistant prostate cancer (CRPC).
Lundbeck to buy Netherlands’ Prexton Therapeutics for €905m
Danish pharmaceutical company Lundbeck has agreed to purchase Netherlands-based Prexton Therapeutics for a total consideration of up to €905m.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.